| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1997PNAS...94.9389R |
| P356 | DOI | 10.1073/PNAS.94.17.9389 |
| P932 | PMC publication ID | 23200 |
| P698 | PubMed publication ID | 9256492 |
| P5875 | ResearchGate publication ID | 13962700 |
| P50 | author | Pradipsinh K. Rathod | Q88838215 |
| P2093 | author name string | P C Lee | |
| T McErlean | |||
| P2860 | cites work | Interactions among mutations affecting spontaneous mutation, mitotic recombination, and DNA repair in yeast | Q27932502 |
| Human malaria parasites in continuous culture | Q28131626 | ||
| The significance of responses of the genome to challenge | Q28913697 | ||
| Biochemistry of multidrug resistance mediated by the multidrug transporter | Q29616476 | ||
| Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy | Q34058524 | ||
| Evidence for a switching mechanism in the invasion of erythrocytes by Plasmodium falciparum | Q34259232 | ||
| Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance. | Q35123681 | ||
| Kinetics of Plasmodium falciparum thymidylate synthase: interactions with high-affinity metabolites of 5-fluoroorotate and D1694 | Q35125528 | ||
| Drug resistant malaria, with special reference to Thailand | Q35220189 | ||
| Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential | Q35312006 | ||
| Mutator phenotypes in mammalian cell mutants with distinct biochemical defects and abnormal deoxyribonucleoside triphosphate pools | Q35350889 | ||
| Antimalarial activity of a combination of 5-fluoroorotate and uridine in mice | Q35565199 | ||
| Antimalarial drug resistance: the pace quickens | Q35665093 | ||
| Selection and characterization of 5-fluoroorotate-resistant Plasmodium falciparum | Q35823321 | ||
| Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum | Q35845458 | ||
| Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria | Q35846117 | ||
| Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance | Q37739332 | ||
| Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria | Q37739425 | ||
| The prevention of antimalarial drug resistance | Q38036281 | ||
| Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand | Q39188543 | ||
| The treatment of malaria | Q39590029 | ||
| Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. | Q39596634 | ||
| Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro | Q39833070 | ||
| In vitro activities of and mechanisms of resistance to antifol antimalarial drugs | Q39849631 | ||
| Multidrug resistance and P-glycoproteins in parasitic protozoa | Q40456798 | ||
| Mismatch repair, genetic stability, and cancer | Q40556409 | ||
| DNA repair genes and proteins of Saccharomyces cerevisiae | Q40722184 | ||
| DNA-replication fidelity, mismatch repair and genome instability in cancer cells | Q41016785 | ||
| Mechanisms of drug resistance in malaria | Q41082076 | ||
| Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization | Q41928982 | ||
| Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite | Q41929069 | ||
| The chemotherapy of rodent malaria, XXVI. The potential value of WR 122,455 (a 9-phenanthrenemethanol) against drug-resistant malaria parasites | Q41930920 | ||
| Genetics of chloroquine resistance in malaria parasites | Q41931098 | ||
| Plasmodium vinckei: production of chloroquine-resistant strain | Q41938885 | ||
| Molecular genetics of drug resistance in Plasmodium falciparum malaria | Q41942588 | ||
| Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross | Q41943911 | ||
| Plasmodium vivax resistance to chloroquine? | Q41945108 | ||
| Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro | Q42206978 | ||
| Genetic analysis of the human malaria parasite plasmodium falciparum | Q44150753 | ||
| Plasmodium falciparum: recrudescence of parasites in culture | Q44920592 | ||
| Compartmentalization of genes coding for immunodominant antigens to fragile chromosome ends leads to dispersed subtelomeric gene families and rapid gene evolution in Plasmodium falciparum | Q46308305 | ||
| Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair | Q46617407 | ||
| Atovaquone - a novel broad-spectrum anti-infective drug | Q47996681 | ||
| Reduced resources applied to antimalarial drug development | Q47996713 | ||
| A membrane network for nutrient import in red cells infected with the malaria parasite | Q48036713 | ||
| Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion | Q67285620 | ||
| Plasmodium falciparum: a high proportion of parasites from a population of the Dd2 strain are able to invade erythrocytes by an alternative pathway | Q73335510 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| P304 | page(s) | 9389-9393 | |
| P577 | publication date | 1997-08-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Variations in frequencies of drug resistance in Plasmodium falciparum | |
| P478 | volume | 94 |
| Q36612497 | A Bioinformatics Approach for Homology Modeling and Binding Site Identification of Triosephosphate Isomerase from Plasmodium falciparum 3D7. |
| Q35563452 | A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor |
| Q36340996 | A framework for assessing the risk of resistance for anti-malarials in development |
| Q28474023 | A genetically hard-wired metabolic transcriptome in Plasmodium falciparum fails to mount protective responses to lethal antifolates |
| Q28469012 | A systematic map of genetic variation in Plasmodium falciparum |
| Q34515934 | Anopheles subpictus carry human malaria parasites in an urban area of Western India and may facilitate perennial malaria transmission |
| Q52609454 | Anti-plasmodial effect of plant extracts from Picrolemma huberi and Picramnia latifolia. |
| Q35840382 | Antimalarial combinations |
| Q41921517 | Antimalarial drug combination policy: a caveat |
| Q22061790 | Antimalarial drug resistance |
| Q35212414 | Antimalarial drug resistance and combination chemotherapy |
| Q40106428 | Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic |
| Q22061852 | Artemisinin Resistance in Plasmodium falciparum Malaria |
| Q22061805 | Artemisinin and a Series of Novel Endoperoxide Antimalarials Exert Early Effects on Digestive Vacuole Morphology |
| Q21032505 | Artemisinin resistance: current status and scenarios for containment |
| Q24614989 | Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria |
| Q28533270 | Asexual populations of the human malaria parasite, Plasmodium falciparum, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications |
| Q25257654 | Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure |
| Q42725889 | Benzothiophene carboxamide derivatives as inhibitors of Plasmodium falciparum enoyl-ACP reductase |
| Q30044485 | Biochemical and functional characterization of Plasmodium falciparum GTP cyclohydrolase I |
| Q37924296 | Challenges in antimalarial drug discovery |
| Q52627214 | Checks and balances? DNA replication and the cell cycle in Plasmodium. |
| Q36093316 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets |
| Q24540624 | Comparative whole genome transcriptome analysis of three Plasmodium falciparum strains |
| Q33981743 | Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparum |
| Q63976815 | Complex DNA structures trigger copy number variation across the Plasmodium falciparum genome |
| Q24814551 | Concurrence of Plasmodium falciparum dhfr and crt mutations in northern Ghana |
| Q92013843 | Coupling the Antimalarial Cell Penetrating Peptide TP10 to Classical Antimalarial Drugs Primaquine and Chloroquine Produces Strongly Hemolytic Conjugates |
| Q35598598 | Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen |
| Q36754647 | DNA damage regulation and its role in drug-related phenotypes in the malaria parasites |
| Q34535074 | DNA microarrays for malaria |
| Q21032539 | Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border |
| Q34438056 | Defining and interpreting intraspecific molecular variation |
| Q35354508 | Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines |
| Q35006418 | Discovery, mechanisms of action and combination therapy of artemisinin |
| Q24550694 | Drug targets and mechanisms of resistance in the anaerobic protozoa |
| Q37870388 | Drug-resistant malaria: molecular mechanisms and implications for public health |
| Q92909773 | ELQ-331 as a prototype for extremely durable chemoprotection against malaria |
| Q34058304 | Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reports |
| Q34343530 | Emerging artemisinin resistance in the border areas of Thailand |
| Q37217964 | Essential protein-protein interactions between Plasmodium falciparum thymidylate synthase and dihydrofolate reductase domains |
| Q28551519 | Evidence of a Mild Mutator Phenotype in Cambodian Plasmodium falciparum Malaria Parasites |
| Q33558392 | Extreme mutation bias and high AT content in Plasmodium falciparum |
| Q38399949 | Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance |
| Q30362459 | Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites |
| Q28030935 | Genetic architecture of artemisinin-resistant Plasmodium falciparum |
| Q37445383 | Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum |
| Q39740635 | Genetics of mefloquine resistance in the rodent malaria parasite Plasmodium chabaudi |
| Q24625172 | Genome scanning of Amazonian Plasmodium falciparum shows subtelomeric instability and clindamycin-resistant parasites |
| Q28481274 | Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressure |
| Q31076495 | Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya |
| Q103826190 | Genomic surveillance of Plasmodium falciparum and Plasmodium vivax cases at the University Hospital in Tegucigalpa, Honduras |
| Q26824875 | Global phenotypic screening for antimalarials |
| Q31156888 | High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase |
| Q37802635 | How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance |
| Q37822758 | How can we identify parasite genes that underlie antimalarial drug resistance? |
| Q55054343 | How to combat emerging artemisinin resistance: Lessons from "The Three Little Pigs". |
| Q36327112 | Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors |
| Q30277705 | In vitro adaptation of Plasmodium falciparum reveal variations in cultivability. |
| Q37119350 | In vitro selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemisinin |
| Q33636206 | In vitro selection of Plasmodium falciparum drug-resistant parasite lines |
| Q34151002 | In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger |
| Q28484068 | In vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genes |
| Q34602866 | Invasion of Africa by a single pfcrt allele of South East Asian type |
| Q37208414 | Large-scale genotyping and genetic mapping in Plasmodium parasites. |
| Q92822814 | Lead Optimization of Dehydroemetine for Repositioned Use in Malaria |
| Q35532863 | Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations |
| Q39188733 | Malaria Epigenetics |
| Q35558706 | Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes |
| Q34785704 | Malaria drug resistance is associated with defective DNA mismatch repair |
| Q35799623 | Malaria ecology along the Thailand-Myanmar border |
| Q37488243 | Malaria evolution in South Asia: knowledge for control and elimination |
| Q21032492 | Malaria in the Greater Mekong Subregion: heterogeneity and complexity |
| Q34352253 | Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. |
| Q37417056 | Malaria parasites utilize both homologous recombination and alternative end joining pathways to maintain genome integrity |
| Q36538784 | Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria |
| Q36269058 | Mechanisms of in vitro resistance to dihydroartemisinin in Plasmodium falciparum |
| Q34552816 | Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs |
| Q42256920 | Microbiology. Eliminating malaria |
| Q34309434 | Mitochondrial Electron Transport Inhibition and Viability of Intraerythrocytic Plasmodium falciparum |
| Q28486079 | Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families |
| Q33971977 | Modelling a predictable disaster: the rise and spread of drug-resistantmalaria |
| Q35635612 | Molecular epidemiology of malaria |
| Q37253966 | Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia |
| Q36276918 | Mutation in the Plasmodium falciparum CRT protein determines the stereospecific activity of antimalarial cinchona alkaloids |
| Q43630972 | Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum |
| Q39474607 | Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site |
| Q41943991 | Mutations in transmembrane domains 1, 4 and 9 of the Plasmodium falciparum chloroquine resistance transporter alter susceptibility to chloroquine, quinine and quinidine |
| Q41920840 | New insight into the mechanism of accumulation and intraerythrocytic compartmentation of albitiazolium, a new type of antimalarial. |
| Q89864921 | Novel endochin-like quinolones exhibit potent in vitro activity against Plasmodium knowlesi but do not synergise with proguanil |
| Q30663600 | Of mice and malaria mutants: unravelling the genetics of drug resistance using rodent malaria models |
| Q30581496 | Origin of robustness in generating drug-resistant malaria parasites |
| Q52655962 | Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites. |
| Q35666578 | Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum |
| Q35139505 | Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites |
| Q31034559 | Plasmodium biology: genomic gleanings |
| Q33903812 | Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy |
| Q34678568 | Plasmodium drug targets outside the genetic control of the parasite |
| Q37414137 | Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes |
| Q35121790 | Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine |
| Q35047872 | Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype |
| Q41918613 | Plasmodium falciparum pfcrt and pfmdr1 polymorphisms are associated with the pfdhfr N108 pyrimethamine-resistance mutation in isolates from Ghana |
| Q37849394 | Population biological principles of drug-resistance evolution in infectious diseases |
| Q33979229 | Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum |
| Q35156257 | Predicting functional and regulatory divergence of a drug resistance transporter gene in the human malaria parasite |
| Q44163969 | Presidential address. Classical is critical: alleviating the burden of parasitic diseases |
| Q37035250 | Prevalence of pfmdr1, pfcrt, pfdhfr and pfdhps mutations associated with drug resistance, in Luanda, Angola |
| Q37585368 | Prodrugs of bisthiazolium salts are orally potent antimalarials |
| Q36381243 | Proteomics of the human malaria parasite Plasmodium falciparum |
| Q28649962 | Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum |
| Q21032477 | Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum |
| Q28473721 | Regulatory hotspots in the malaria parasite genome dictate transcriptional variation |
| Q27641065 | Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase |
| Q45231874 | Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum |
| Q38755043 | Resisting resistance: is there a solution for malaria? |
| Q28475957 | Retention and loss of RNA interference pathways in trypanosomatid protozoans |
| Q36050791 | Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites |
| Q38866063 | Salinomycin and other ionophores as a new class of antimalarial drugs with transmission-blocking activity |
| Q41913918 | Selection of cysteine protease inhibitor-resistant malaria parasites is accompanied by amplification of falcipain genes and alteration in inhibitor transport |
| Q56378245 | Selection of cytochrome B mutants by putative PfNDH2 inhibitors |
| Q35596128 | Sexual recombination is a signature of a persisting malaria epidemic in Peru |
| Q30832639 | Shotgun DNA microarrays and stage-specific gene expression in Plasmodium falciparum malaria |
| Q24606915 | Spiroindolones, a potent compound class for the treatment of malaria |
| Q47917880 | Stochastic versus stable transcriptional differences on Plasmodium falciparum DNA microarrays |
| Q27861940 | Structural polymorphism in the promoter ofpfmrp2confersPlasmodium falciparumtolerance to quinoline drugs |
| Q39022462 | Synthesis, biological evaluation and structure-activity relationships of new quinoxaline derivatives as anti-Plasmodium falciparum agents. |
| Q37894700 | Target identification and validation of novel antimalarials |
| Q35200259 | The "Malaria's Eve" hypothesis and the debate concerning the origin of the human malaria parasite Plasmodium falciparum. |
| Q36051237 | The Redox Cycler Plasmodione Is a Fast-Acting Antimalarial Lead Compound with Pronounced Activity against Sexual and Early Asexual Blood-Stage Parasites |
| Q73138568 | The de novo selection of drug-resistant malaria parasites |
| Q92231044 | The genomic architecture of antimalarial drug resistance |
| Q24802251 | The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin |
| Q37139259 | The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia |
| Q30045892 | Topoisomerase II from Human Malaria Parasites: EXPRESSION, PURIFICATION, AND SELECTIVE INHIBITION |
| Q42324155 | Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate |
| Q37057973 | Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. |
| Q36895688 | Using the genome to dissect the molecular basis of drug resistance. |
| Q30045658 | Validation of isoleucine utilization targets in Plasmodium falciparum |
| Q35492470 | Variable numbers of tandem repeats in Plasmodium falciparum genes |
| Q36914971 | Variation in infection length and superinfection enhance selection efficiency in the human malaria parasite |
| Q35822252 | Within-Host Selection of Drug Resistance in a Mouse Model of Repeated Incomplete Malaria Treatment: Comparison between Atovaquone and Pyrimethamine |
Search more.